Ixekizumab Eases Psoriatic Arthritis When TNF Inhibitor Fails Ixekizumab Eases Psoriatic Arthritis When TNF Inhibitor Fails

The selective interleukin-17A inhibitor ixekizumab improved signs and symptoms of active psoriatic arthritis (PsA) in patients who had failed prior biologic therapy in the phase 3 SPIRIT-P2 trial.Reuters Health Information
Source: Medscape Dermatology Headlines - Category: Dermatology Tags: Dermatology News Source Type: news